Skip to main content
Efficacy and safety of Atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (April-SLE randomised trial)
Published Web Location
http://europepmc.org/articles/PMC4680140?pdf=renderNo data is associated with this publication.
Abstract
Objectives: Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferationinducing ligand, which are increased
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.